Clinical Trial Update: Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation [Phase 2]

View source ↗

Summary

Phase 2 study assessing VX-661 (tezacaftor) alone and in combination with ivacaftor in people with the F508del CFTR mutation; trial completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• VX-661 (tezacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2018-04-13